Edwards Lifesciences Co. (NYSE:EW) Stock Position Boosted by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio raised its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300,202 shares of the medical research company's stock after buying an additional 22,731 shares during the period. Public Employees Retirement System of Ohio owned about 0.05% of Edwards Lifesciences worth $19,810,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock valued at $2,080,845,000 after buying an additional 14,610,123 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock worth $243,745,000 after purchasing an additional 2,606,950 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company's stock worth $1,827,347,000 after purchasing an additional 809,605 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock valued at $599,078,000 after purchasing an additional 806,705 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $39,628,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.5 %

NYSE:EW traded up $0.39 on Wednesday, hitting $73.78. 3,593,751 shares of the stock were exchanged, compared to its average volume of 4,652,855. The stock has a fifty day moving average of $68.92 and a 200-day moving average of $74.19. The stock has a market cap of $43.52 billion, a PE ratio of 10.60, a PEG ratio of 3.52 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business's quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 earnings per share. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a "hold" rating in a research note on Thursday, December 5th. Evercore ISI decreased their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Thursday, December 5th. Truist Financial reaffirmed a "hold" rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research note on Wednesday. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $78.65.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,000 shares of company stock worth $2,323,150. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.